BEACONSOFT CLOSING ANNOUNCEMENT

We published Beaconsoft because of a) their unique and leading edge offering in the Martech sector [Stakeholderz uses Beaconsoft], and b) the strength of their management team. Their leadership and commitment throughout the the raise has been outstanding.

We have driven investor engagement in a number of ways: promotion to our extensive network, creating a 1,000 strong affinity group, two Pitch and Networking events, 3 informal CEOs drinks, a live webinar Fireside Chat, and a prestigious Summit Dinner at Coutts Bank. We have been very impressed by the following of their original investors into this round and we see this as a major endorsement of our strong belief in this company. We see Beaconsoft as being extremely well positioned for their next funding round in 2020.

Nigel Bridges, CEO of Beaconsoft, said ‘We have been aware that our breakthrough technology would enable us to be a potential leader amongst the next generation of MarTech products and, in time, potentially into wider global markets. Stakeholderz has been an excellent partner to work with; helping us to refine our investment proposition and then delivering on opportunities to talk to potential investors. In closing this round through both new investors and existing investors, we have been very impressed with the support from Stakeholderz and look forward to a continuing relationship into the future.’

Previous Post
WHEN STAKEHOLDERZ MET ZAEL PRESTEL
Next Post
STAKEHOLDERZ IN THE SPOTLIGHT

Latest News

Recap of our recent Neuroscience Investor Event

We’re excited to share some highlights from our recent Neuroscience Investor Event with Nevrargenics Ltd. The event, held on April 9th, 2024, was a fantastic gathering of business professionals, investors,…
Read more

Featured Events

Neuroscience Company Presentation

Tuesday

9 April 2024

The issue: Neurodegenerative diseases affect over a billion people worldwide; the human and economic cost of diseases like Fronto Temporal Dementia, Motor Neurone Disease (ALS, MND), Alzheimer’s, Parkinson’s and MS…
Read more
keyboard_arrow_up